The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes by Polymenidou, M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
The POM monoclonals: a comprehensive set of antibodies to
non-overlapping prion protein epitopes
Polymenidou, M; Moos, R; Scott, M; Sigurdson, C; Shi, Y Z; Yajima, B; Hafner-Bratkovic, I; Jerala, R;
Hornemann, S; Wuthrich, K; Bellon, A; Vey, M; Garen, G; James, M N G; Kav, N; Aguzzi, A
Abstract: PrP(Sc), a misfolded and aggregated form of the cellular prion protein PrP(C), is the only
defined constituent of the transmissible agent causing prion diseases. Expression of PrP(C) in the host
organism is necessary for prion replication and for prion neurotoxicity. Understanding prion diseases
necessitates detailed structural insights into PrP(C) and PrP(Sc). Towards this goal, we have developed
a comprehensive collection of monoclonal antibodies denoted POM1 to POM19 and directed against
many different epitopes of mouse PrP(C). Three epitopes are located within the N-terminal octarepeat
region, one is situated within the central unstructured region, and four epitopes are discontinuous within
the globular C-proximal domain of PrP(C). Some of these antibodies recognize epitopes that are resilient
to protease digestion in PrP(Sc). Other antibodies immunoprecipitate PrP(C), but not PrP(Sc). A
third group was found to immunoprecipitate both PrP isoforms. Some of the latter antibodies could be
blocked with epitope-mimicking peptides, and incubation with an excess of these peptides allowed for
immunochromatography of PrP(C) and PrP(Sc). Amino-proximal antibodies were found to react with
repetitive PrP(C) epitopes, thereby vastly increasing their avidity. We have also created functional single-
chain miniantibodies from selected POMs, which retained the binding characteristics despite their low
molecular mass. The POM collection, thus, represents a unique set of reagents allowing for studies with a
variety of techniques, including western blotting, ELISA, immunoprecipitation, conformation-dependent
immunoassays, and plasmon surface plasmon resonance-based assays.
DOI: 10.1371/journal.pone.0003872
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-9277
Veröffentlichte Version
 
 
Originally published at:
Polymenidou, M; Moos, R; Scott, M; Sigurdson, C; Shi, Y Z; Yajima, B; Hafner-Bratkovic, I; Jerala, R;
Hornemann, S; Wuthrich, K; Bellon, A; Vey, M; Garen, G; James, M N G; Kav, N; Aguzzi, A (2008).
The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes.
PLoS ONE, 3(12):e3872. DOI: 10.1371/journal.pone.0003872
The POM Monoclonals: A Comprehensive Set of
Antibodies to Non-Overlapping Prion Protein Epitopes
Magdalini Polymenidou1¤a, Rita Moos1, Mike Scott2¤c, Christina Sigurdson1¤b, Yong-zhong Shi5, Bill
Yajima3, Iva Hafner-Bratkovicˇ6, Roman Jerala6,7, Simone Hornemann8, Kurt Wuthrich8,9, Anne Bellon10,
Martin Vey10, Graciela Garen3,4, Michael N. G. James4, Nat Kav3, Adriano Aguzzi1*
1 Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland, 2 Functional Genomics Center Zurich, ETH/University of Zu¨rich, Zu¨rich, Switzerland,
3Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada, 4Department of Biochemistry, University of Alberta,
Edmonton, Alberta, Canada, 5Alberta Research Council, Edmonton, Alberta, Canada, 6Department of Biotechnology, National Institute of Chemistry, University of
Ljubljana, Ljubljana, Slovenia, 7 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia, 8 Institut fu¨r Molekularbiologie und Biophysik,
ETH Zu¨rich, Zu¨rich, Switzerland, 9Department of Molecular Biology and Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United
States of America, 10 ZLB Behring, Marburg, Germany
Abstract
PrPSc, a misfolded and aggregated form of the cellular prion protein PrPC, is the only defined constituent of the
transmissible agent causing prion diseases. Expression of PrPC in the host organism is necessary for prion replication and for
prion neurotoxicity. Understanding prion diseases necessitates detailed structural insights into PrPC and PrPSc. Towards this
goal, we have developed a comprehensive collection of monoclonal antibodies denoted POM1 to POM19 and directed
against many different epitopes of mouse PrPC. Three epitopes are located within the N-terminal octarepeat region, one is
situated within the central unstructured region, and four epitopes are discontinuous within the globular C-proximal domain
of PrPC. Some of these antibodies recognize epitopes that are resilient to protease digestion in PrPSc. Other antibodies
immunoprecipitate PrPC, but not PrPSc. A third group was found to immunoprecipitate both PrP isoforms. Some of the latter
antibodies could be blocked with epitope-mimicking peptides, and incubation with an excess of these peptides allowed for
immunochromatography of PrPC and PrPSc. Amino-proximal antibodies were found to react with repetitive PrPC epitopes,
thereby vastly increasing their avidity. We have also created functional single-chain miniantibodies from selected POMs,
which retained the binding characteristics despite their low molecular mass. The POM collection, thus, represents a unique
set of reagents allowing for studies with a variety of techniques, including western blotting, ELISA, immunoprecipitation,
conformation-dependent immunoassays, and plasmon surface plasmon resonance-based assays.
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Introduction
Although the first anti-PrP antisera were first reported in 1984
[1], generation of high affinity monoclonal anti-PrP antibodies has
been hindered for a long time by the fact that wild type mice are
immunotolerant against PrP [2–4]. A widely used mouse
monoclonal antibody, designated 3F4, was produced by immu-
nizing mice with large amounts of purified SHaPrP27-30 [5]. 3F4
recognizes a hamster and human-specific PrP heptapeptide
epitope, largely determined by methionine at positions 109 and
112 of hamster and human PrP, which is replaced with leucine
and valine respectively in mouse PrP [6,7]. However, a high level
of PrP sequence conservation among species [8] limited the
possibility of raising antibodies against species-specific epitopes
and only a handful of high affinity antibodies were produced in
wild type mice.
With the creation of Prnpo/o mice this obstacle was overcome
[9,10] and a number of very efficient monoclonal anti-PrP
antibodies have been created by immunizing those mice with a
variety of protocols from antibody-phage technology [11] to
liposome preparations [12], DNA immunization [13], and
recombinant protein [14,15]. However, many of the currently
available anti-PrP antibodies have specificities directed against the
central and C-terminal part of the molecule. This results in part
from the choice of antigen (purified PrP27-30) in most previous
attempts to generate anti-PrP antibodies, from which the flexible
unstructured N-terminal part of PrP is excluded.
We have developed and characterized a panel of novel anti-PrP
monoclonal antibodies, with the goal of gaining new specificities
towards PrP. These antibodies, designated POM1 through
POM19, are directed against various epitopes spanning the entire
sequence of the mature prion protein including the previously
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underrepresented N-terminal part. Some of those antibodies were
previously shown to discriminate PK-digested PrPSc from different
strains [16] thereby providing valuable tools for the biochemical
characterization of prion strains [17] as well as for other aspects of
prion research and diagnosis.
Results
Antibody production and selection
Using active immunization of Prnpo/o mice with bacterially
produced recombinant mouse PrP (rmPrP23-231; numbering
according to the human prion protein), we induced potent
immune responses towards various protein-epitopes of PrP.
Consequently, splenocytes of immunized mice were fused with
the immortalized myeloma cell line Sp2/0-Ag14. Supernatants of
growing clones were then screened for binding to rmPrP23-231 by
Western Blot (WB) and ELISA. 55 positive clones were identified
and were further analyzed by Western blot of brain homogenates
from terminally scrapie sick mice (Supplementary Figure S1). This
screen revealed several antibodies that performed well on western
blotting, such as clones 75, 590, and 1193, henceforth named
POM4, POM13, and POM1 respectively. Some other clones
recognized mono and unglycosylated PrP, but not diglycosylated
PrPC; these included clones POM4 (75), POM5 (141), and POM8
(248). Since the immunization was performed using bacterially
produced rmPrP23-231 which is not glycosylated, the paratopes are
unlikely to be directed against a glycan epitope. Instead it is likely
that one of the two glycan chains sterically hinders the epitopes of
those clones. Further experiments revealed that while these
antibodies preferentially bind to mono and unglycosylated PrP,
they also bind to diglycosylated molecules with reduced binding
strength (e.g. in Supplementary Figure S4A).
Subsequently, all 55 clones were screened for binding to native
PrPC as it is displayed on the cell surface (Supplementary Figure S2).
To this end, blood cells from transgenic mice overexpressing PrP
specifically on T-cells [18] were used and all clones were compared
directly to the previously described monoclonal antibody 6H4 [15]
using flow cytometry. Many clones showed PrP-binding with
fluorescent intensity of up to one log higher than that of 6H4. Based
on this first screen of 55 positive clones, 19 most interesting clones
were selected for further characterization, designated POM1–19
(Supplementary Figure S1 and S2, red frames).
Isotyping and peptide mapping
Immunoglobulin (Ig)-isotype specific ELISA was performed
using POM1–POM19. In a first screening round, plates were
coated with N-terminally truncated recombinant mPrP comprising
residues 121–231 (rmPrP121-231). After incubation with POM
hybridoma supernatant, ELISA plates were incubated with HRP-
labeled isotype-specific anti-mouse antibodies. Some POMs
showed no binding on rmPrP121-231, indicating that their epitopes
are located within the amino proximal part of PrP (data not
shown). When full length protein was used for coating, those
clones that were nonreactive with rmPrP121-231 yielded positive
signals, and their Ig isotype was identified. Most of the POMs were
found to be of the IgG1 isotype, with very few exceptions. This
experiment allowed us to group the POMs into those reacting with
epitopes either in the ‘unstructured’ N-terminal or in the
structured PrP-domain 121–231 [16].
To further specify the epitopes of POM antibodies, a library of
synthetic peptides spanning the whole PrP sequence was
constructed. It consisted of 100 dodecameric peptides spanning
PrP shifted by 2 amino acids. Using this library, competition-
ELISA experiments were performed. To this end, plates were
coated with rmPrP23-231 and incubated with POM-hybridoma cell
supernatant in presence or absence of excess amounts of PrP
peptides. Whenever the included peptide corresponded to the
cognate epitope of the antibody, binding to rmPrP23-231 was
reduced or abolished.
Epitope mapping was performed in two steps. First, competition
ELISA was performed using pools of 10 sequential peptides
(Figure 1, all left panels). Inhibition of binding by one or two
peptide pools exposed the PrP area that includes the epitope of
each antibody. For example for POM2, peptides P11–P20 and
P21–P30 competed meaning that the epitope is between amino
acids 43–92 of mouse PrP. Subsequently, single peptides of the
competing pool were used and the exact epitopes of POM2, 3, 11,
12, and 14 were identified (Figure 1, all right panels). Interestingly,
of the five N-terminal antibodies mapped by this method, 4 have
specificities on the octarepeat region of the PrP and only POM3
has an epitope downstream of the octarepeat region (HNQWNK,
amino acids 95–100). This apparent increased immunogenicity of
the octarepeat region is possibly due to its repetitive nature. POM2
and 12 seemed to recognize the same octapeptide, namely
GQPHGGG/SW, which is located at 57–64, 64–72, 72–80 and
80–88 of mouse PrP and can carry either a glycine or a serine as
the seventh residue. POM11 reacted mainly to octarepeats with
serine on the seventh position, meaning amino acids 64–72 and
72–80 (GQPHGGSW); a similar sequence with glycine instead of
serine showed lower competition efficiency (GQPHGGGW,
residues 57–64 and 80–88). Finally, POM14 reacted with a 12-
mer peptide resulting from two sequential octarepeats GGT/G/
SWGQPHGGG/SW, scanning the overlapping PrP stretches 53–
64, 61–72, 69–80 and 77–88. All octarepeat specific POMs have
multiple epitopes on PrP. The POM2/12 epitope appears 4
sequential times on PrP, POM11 twice and POM14, 4 times that
overlap twice, due to its length which is more than 8 amino acids.
Competition ELISA experiments were very informative for all
N-terminal specific antibodies, but none of the C-terminal specific
antibodies (binding on rmPrP121-231) could be mapped by this
method (Figure 2). We then devised a panel of 19 longer synthetic
peptides (25-mers) spanning the globular domain of the PrP
sequence (amino acids 111–225) shifted by 5 amino acids each.
The peptides were coupled on ELISA plates and binding of
different POMs was assessed through a direct ELISA protocol.
Full-length and N-terminally truncated rmPrP121-231 as well as a
25-mer spanning the octarepeat region were used as positive
controls (Figure 3). While the octarepeat-specific POM11 clearly
recognized both rmPrP23-231 and the octarepeat-mimicking
peptides (amino acids 65–89), most C-terminal antibodies – with
the exception of POM4 and POM10 – bound only rmPrP23-231
and rmPrP121-231 but none of the immobilized peptides. POM4,
POM10 (Figure 3), and POM19 (not shown) bound a C-terminal
peptide spanning amino acids 201–225, indicating that their
epitopes are contained within that region. All other C-terminal
antibodies tested however – including 6H4 – showed no or poor
binding to the 25-mers and therefore gave limited information on
their epitope specificity.
A very plausible explanation for this result is that POMs binding
to the structured part of PrP identify either discontinuous or
conformational epitopes that cannot be simulated by using short
linear peptides. The complete segregation of short linear vs. long
or discontinuous epitopes was entirely unexpected: not a single
antibody to the structured region of PrP could be competed with
linear dodecameric peptides, whereas all antibodies to the
unstructured amino proximal region or to the very far carboxy
terminal end of PrP, without any exception, were efficiently
competed by cognate peptides.
Anti-Prion Protein Antibodies
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Pair-wise mapping by surface plasmon resonance
To overcome the epitope-mapping obstacles and to learn more
about the binding specificities of the C-terminal POMs, surface
plasmon resonance (SPR) technology was used in order to compile
complementation groups of mAbs with non-competing epitopes.
With this methodology it is possible to identify fully complemen-
tary mAb pairs that would not sterically hinder the binding of each
other to the same protein, e.g. for establishing a highly sensitive
sandwich ELISA for PrPC and/or PrPSc. Notably, this strategy was
expected to function even if the exact epitopes of the antibodies
are not known. In addition, competition experiments with 6H4, a
previously mapped C-terminal anti-PrP antibody [15], could
identify POM antibodies with epitopes in the vicinity of the 6H4
epitope (144–152 of mouse PrP).
In pair-wise mapping experiments, one antibody is immobilized
on the chip surface by a covalent bond and captures recombinant
mPrP that is consequently injected in solution. Next, a second
antibody is injected and binding events are observed. If the second
antibody has an epitope that competes with the capturing antibody
it will not bind. On the contrary, if it has a non-competing epitope,
it binds on PrP captured by the immobilized antibody (Figure 4A).
A representative sensogram for immobilized POM6 is shown in
Figure 4B. In this case, bovine serum albumin (BSA) was used as a
negative control protein which did not bind to POM6. After
capturing of rmPrP121-231, POM6 was injected again and, as
expected, no binding was observed (same antibody= same
epitope). Instead a gradual decrease in response units implies a
slow dissociation of PrP. When POM1 was subsequently injected,
no binding occurred on the chip surface. On the contrary, during
POM1 injection the dissociation curve of rmPrP121-231 is
augmented, indicating that POM1 is ‘stripping’ PrP from the
POM6-coated surface. This suggests that POM1 binds an epitope
that competes with POM6 for binding to PrP. POM4 is injected
last and it shows a potent binding on the POM6-captured-PrP,
demonstrating that it binds independently of POM6 epitope.
Similar sensograms were obtained for immobilized POM1, 4, 5,
6, 7, 8, and 9 with all other C-terminal POMs as well as 6H4 (data
not shown). The results are summarized in Figure 4C. Pair-wise
mapping of C-terminal POM antibodies performed by SPR
demonstrated that all competing pairs of antibodies antagonized
each other’s binding in both orientations, independently of
whether a mAb was immobilized or in solution, confirming the
validity of these experiments. POM5 appears to have a unique
epitope that can be combined with any other POM or with 6H4
without competition. POM4 competed only with POM10 and
POM19, pointing out that these three antibodies cluster together,
potentially sharing the same epitope. Antibodies POM1, 6, 7, 8
and 9 competed with 6H4 indicating that their epitopes lay in the
vicinity of residues 144–152 of mouse PrP that correspond to 6H4
epitope. In addition, all C-terminal antibodies tested by pair-wise
mapping on the SPR instrument, showed competition with
themselves meaning that when PrP was captured by a particular
antibody, the same antibody could not bind on PrP, when injected
in solution. This was not surprising, since its epitope was blocked
by the capturing moiety coupled to the chip surface. However,
when the octarepeat specific antibodies POM2 and 12 were tested
on the same setup, results looked different. As already mentioned,
POM2 and 12 have epitopes that appear 4 sequential times on the
N-terminus of PrP. This is probably why, when rmPrP23-231 is
captured by POM12, some epitopes remain available for further
binding when the same antibody is re-injected in solution [16].
POM1, 2, 3, 4, and 9 were biotinylated and used with their non-
biotinylated equivalents for capturing and detecting recombinant
mPrP in all possible combinations and orientations in a sandwich
ELISA protocol (Supplementary Figure S3). As observed by SPR,
POM2 was the only antibody that could be used simultaneously as
capturing and detecting reagent (Supplementary Figure S3A–E).
POM2 was also the most potent capturing antibody showing
highest titers, independently of the detecting antibody (Supple-
mentary Figure S3A–E). Furthermore, combination of POM1 and
Figure 2. Linear 12-meric peptides do not compete with binding of C-terminal POMs to PrP. Binding of POM1 to immobilized rmPrP23-231
could be competed by excess amounts of N-terminally truncated rmPrP121-231 (A), but not with any of the PrP peptide pools (B) in contrast to all N-
terminally specific POMs shown in Figure 1.
doi:10.1371/journal.pone.0003872.g002
Figure 1. Competition ELISA and epitopes of N-terminal specific POMs. Competition ELISA with pools of 10 sequential peptides (all left
panels) revealed a broad area of PrP including the epitope of each antibody; for example P11–P20 and P21–P30 for POM2 and P31–P40 for POM3.
Subsequently, competition with single peptides (all right panels) representing the ones included in the competing pool from the left panel, identified
the exact epitopes of POM2, 3, 11, 12 and 14. Note: although the right panels of A and D were previously published in the supplementary data of [16],
we chose to include them here again for completeness.
doi:10.1371/journal.pone.0003872.g001
Anti-Prion Protein Antibodies
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POM9 in either orientation gave only borderline signals
(Supplementary Figure S3A and S3E), confirming competition of
these two antibodies observed by pair-wise mapping in SPR
(Figure 4C). POM4 does not compete with POM1, POM9 or the
N-terminal POM2, as expected. Interestingly, POM3 seems to
partially compete with POM4 only in one orientation, namely
when POM4 is capturing PrP and POM3 is detecting it
(Supplementary Figure S3C), but not in the reverse experiment
(Supplementary Figure S3D). We think that this may be explained
by the observation that a central part of PrP (residues 121–134)
Figure 3. C-terminal POMs do not bind to linear 25-meric PrP-peptides. C-terminal-specific POMs were tested for binding on ELISA plates
containing immobilized 25-meric PrP-peptides or rmPrP for control. While all antibodies bound strongly to rmPrP23-231, only POM4, 10 – and POM19,
not shown – interacted with a 25-mer, spanning amino acids 200–225 of mouse PrP. As positive control, binding of POM11 on the octarepeat region
– peptide 65–89 – was used. As expected POM11 did not interact with N-terminally truncated rmPrP121-231, while all other antibodies tested here did.
When all peptides were mixed together and immobilized on the well (ALL P-MIX) no binding was observed, probably because of the inefficient
amounts of the respective peptides. BLK: Blank.
doi:10.1371/journal.pone.0003872.g003
Anti-Prion Protein Antibodies
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Figure 4. Pair-wise mapping of POM antibodies using surface plasmon resonance. (A) Schematic representation of experimental setup
used pair-wise mapping. One antibody (shown in black) was immobilized on the chip surface and recombinant PrP (red circle) is injected into the
system. Subsequently a second antibody (shown in blue) was injected and binding events were observed. (B) Representative pair wise mapping
experiment with immobilized POM6. BSA is a negative control protein and POM6 re-injected into the system also serves as a negative control
antibody (same antibody used for capturing PrP). RU: Response Units. (C) Summary of POM complementarity groups according to pair-wise mapping
SPR-experiments.
doi:10.1371/journal.pone.0003872.g004
Anti-Prion Protein Antibodies
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participates in the POM4 epitope (see below Figures 6 and S4).
This domain is in the vicinity of the POM3 epitope and may
therefore interfere with the subsequent POM3 binding.
Epitope mapping by Western blotting and cross-species
reactivity
To confirm and explore the grouping of C-terminal POMs that
resulted from pair-wise mapping data and to gain further insight
on their binding specificities and cross-species reactivity, a panel of
wild type and point-mutated recombinant PrP proteins were tested
by western blot. Considering the extremely high conservation of
PrP across species it was fully anticipated that the POM collection
includes mAbs reactive with PrP from other non-murine species.
Indeed, most C-terminal antibodies i.e. POM1, 8, 9, 13, 15, 16
and 17 react with all wild type and mutant proteins, with
intensities comparable to 6H4 (Figure 5A). Nonetheless, the
remaining antibodies exhibited binding patterns reflecting their
particular PrP-binding sites. For instance, POM4, 10 (Figure 5A)
and 19 (not shown) present a common binding pattern, in line with
data obtained by the SPR experiments (Figure 4C). These three
antibodies do not bind to wild-type human and porcine PrP
molecules, most likely due to sequence inconsistencies in residues
necessary for forming the antigen-antibody bond. In addition,
POM4, 10 and 19 do not bind to any of the point-mutants of
human PrP molecules tested, except for the one carrying E219Q
mutation (Figure 5A). Interestingly, this mutation represents a
natural dissimilarity in the primary structure of human PrP versus
most of the other mammals including mice; it is glutamic acid (E)
in humans and glutamine (Q) in most other species. This indicates
that glutamic acid at position 219 of human PrP is largely
responsible for the fact that POM4, 10 and 19 do not bind it, since
binding is regained when it is exchanged with glutamine, i.e. the
mouse-equivalent residue. But porcine PrP also carries a glutamine
at position 219, so why is it not recognized? Two residues away
from the identified ‘hot-spot’ for POM4, 10 and 19 epitopes, at
position 222, porcine PrP has a unique tyrosine (Y) instead of
serine (S) in all other PrPs tested. This substitution is likely the
reason for its incompatibility with the mouse PrP-developed
antibodies. Taken together these results suggest that the epitopes
of these three mAbs lay in the C-terminal part, approximately
around amino acids 218 and 221 of the murine prion protein.
Alternatively, substitution of these residues may result in structural
changes that interfere with binding of POM4, 10 and 19 to PrP.
POM6 and 7 faintly recognized porcine PrP but did not recognize
feline and canine PrP. Sequence dissimilarities at positions 158
and 177 of feline and canine PrP in comparison to all other PrP
molecules tested here may account for this. All antibodies except
POM3 and POM5 were found to bind recombinant cervid PrP as
well as cervid PrPC from brain extracts (data not shown).
Another observation concerns POM5, which shows a unique
binding pattern on several PrP molecules (Figure 5A), just like it
showed a unique POM-competition pattern in the pair-wise
mapping experiments (Figure 4C). POM5 does not bind to mouse
PrP carrying two amino acid substitutions at positions 170 and 174
(S170N, N174T), suggesting that its epitope is located on this exact
area of PrP. Failure of POM5 binding to the mutated mouse PrP
was also confirmed by SPR (data not shown). POM5 also fails to
detect human PrP, possibly due to sequence dissimilarity at
position 168, which increases the negative charge of the protein at
the binding site of POM5 possibly leading to destabilization of the
antibody bond (Figure 5B). As observed at the first screen of the
POM hybridoma supernatants, POM5 has an epitope that is
sterically hindered by one glycan chain of PrP (Supplementary
Figure S1). Based on the predicted localization of POM5 epitope
in the area of 168–174 of mouse PrP, this is most likely the
glycosylation linked to asparagine 181. Figure 5B shows a
sequence alignment of PrPC molecules from different species on
the position of the estimated POM5 epitope.
We went on to test a second panel of mutant PrP proteins, in
which various amino acids were substituted by cysteines. We have
used a silver stain to ensure that the proteins were loaded at similar
levels and we then compared replica blots looking for binding
patterns that reveal information on the specificity of each antibody
(Figure 5C). Surprisingly the differences in the binding patterns
were much less prominent when compared to panel 8A.
Nonetheless, we were able to determine that mutations at positions
140 and 145 of mouse PrP strongly reduced the binding of 6H4,
POM1 and POM17, indicating that these positions are significant
for the epitopes of these antibodies. In the case of 6H4, this is in
accordance with previously published data, since the glutamic acid
at position 145 lies within the published epitope [15]. In addition,
antibodies POM6–POM9 showed reduced binding to both 170/
174 and 140/145 cysteine mutants. Since these two mutants have
cysteine substitutions at distant positions of the protein, the
apparent reduction in the binding suggests either that the epitopes
of POM6–POM9 are discontinued or conformational. Confirming
our previous results, antibodies POM3, POM4, POM5, POM10
and POM19 did not recognize human PrP (Figure 5C).
Further investigation of the C-terminal-specific POMs was
achieved using brain homogenates of transgenic mice expressing
N-terminally truncated PrP variants, designated DE with deletion
of 33–121 amino acids and DF with a longer deletion (33–134)
which includes the hydrophobic central domain of PrP [19].
Results confirmed the specificities of N-terminal POMs, which did
not bind to DE PrP (Figure S4A). In addition, POM5 and POM7
only recognized un- and monoglycosylated PrP bands, due to their
‘glycosylation-sensitive’ epitopes. In contrast to all other POMs
tested, POM2 and 12 identified a protein in Prnpo/o brain
homogenates. This unknown protein of about 37kDa cross reacts
with POM2/12 presumably because of a high degree of identity to
the epitope contained in PrP (Supplementary Figure S4A). All C-
terminal specific antibodies recognized DE-PrP, confirming results
obtained from direct ELISA experiments. Unexpectedly, POM4
and 10 antibodies (and POM19, not shown), did not bind to DF
PrP, in contrast to the rest of the C-terminal-specific POMs
(Supplementary Figure S4B). This indicated that PrP residues
121–134 represent an indispensable component for binding of
POM4, 10 and 19. Conversely, western blots of mutated PrP
proteins indicated that amino acids 219 and 222 are essential for
POM4, 10 and 19 interaction with PrP (Figure 5A). Taken
together, these results suggest that these antibodies recognize a
conformational epitope, consisting of the hydrophobic domain
121–134 and 201–225 of mouse PrP. Alternatively, deletion of this
N-terminal part may result in a conformational change in PrP
leading to the masking of the C-terminal bona fide epitope of
POM4, 10 and 19. PrP residues 121–134 are perfectly conserved
among species. Since POM4, 10 and 19 do not bind human but
only mouse PrP, their epitope must be somehow disrupted in
human PrP-structure, possibly through 201–225, its C-terminal
counterpart. The epitopes of the POM antibodies are summarized
in Figure 6.
Flow cytometry, immunohistochemistry and
immunoprecipitation
Purified POM antibodies were systematically tested for binding
on PrPC by flow cytometry, immunohistochemistry, and for their
capacity to immunoprecipitate PrPC and PrPSc. Performance of
each POM on flow cytometry was compared to that of 6H4 [15],
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which in the past had been often used for visualizing PrPC by flow
cytometry. PrP-overexpressing T-cells [18] from blood were
stained in two steps using purified POMs or 6H4 in equal
concentrations and fluorescently labeled anti-mouse IgG, in order
to compare binding intensities of all mAb as previously described
[4]. Direct comparison to 6H4 with normalized concentrations of
all mAbs revealed that all N-terminal specific POMs bind very
strongly to native PrP as displayed on the surface of live cells
(Supplementary Figure S5). Immunohistochemistry (IHC) on
paraffin embedded brain sections of wild type, Prnpo/o and Tg20
(PrP-overexpressing) mice identified POMs performing extremely
well when a standard PrPC-staining protocol was used (Figure 7).
However, none of the POMs were reactive with PrPSc from prion
infected mouse brain (data not shown).
Binding of POM1–7 to PrPC and PrPSc was also tested using a
standard immunoprecipitation protocol (Figure 8A). Brains from
healthy or terminally scrapie sick mice were homogenized and
then incubated with POM1–7 covalently coupled to paramagnetic
beads as previously described [20]. Precipitated PrPC and PrPSc
were visualized by western blot using biotinylated POM1 and
HRP-labeled avidin. As expected, POM1–7 immunoprecipitated
PrPC from uninfected brain homogenate. However precipitation
of PrPSc was more difficult to evaluate. Plasminogen has been
previously shown to quantitatively immunoprecipitate PrPSc [20]
Figure 5. Cross-species specificities and binding idiosyncrasies of C-terminal specific POMs. (A) Western blot analysis on various wild
type and mutated recombinant PrP proteins identified C-terminal POMs with particular binding patterns indicative for their epitopes (i.e POM4, 5, 6, 7
and 10). Blots were loaded with equal amounts and 6H4 serves as a loading control, since its epitope is conserved among the species tested and is
not affected by the point mutations. (B) PrP sequence alignment of residues 165–182 demonstrating the position of POM5 epitope. (C) Western blot
analysis on PrP variants, with various amino acids substituted by cysteine as indicated. Blots were loaded with equal protein amounts and a silver
stained gel serves as a loading control (first panel). Only mild divergences in the binding patterns of the various POMs were found here. The most
striking one is that 6H4, POM1 and POM17 are binding weaker to rmPrP with cysteine substitutions at positions 140 and 145.
doi:10.1371/journal.pone.0003872.g005
Figure 6. Summary of epitope specificities of POM antibodies. POM2 and 12 bind a degenerative epitope within the octarepeat sequence,
whereas POM11 shows stronger binding to a mouse-specific variation of the sequence – QPHGGSW instead of QPHGGG/SW for the other two. POM3
binds a unique sequence near the centre of the PrP molecule (aa 95–100: HNQWNK). The rest of the POMs bind epitopes within the globular domain
of PrPC and were only approximately defined.
doi:10.1371/journal.pone.0003872.g006
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and was therefore used under identical conditions as positive
control and purified mouse IgG (unspecific) served as negative
control. As recently described, PrPSc interacts with unspecific
immunoglobulins possibly with their Fc moiety [21]. This was
observed here in scrapie infected non-PK-digested brain homog-
enate. However, when the infected homogenate was digested with
PK, no interaction was observed, allowing evaluation of antibodies
binding to PK-digested PrPSc. POM2, 5 and 6 displayed efficient
immunoprecipitation of PK-digested PrPSc (Figure 8A). Whereas
the POM2 epitope lies within the region of PrP that is digested by
PK, at least one POM2 epitope remains in the PK-digested PrPSc
from RML as evidenced by the fact that PrPSc retains POM2
immunoreactivity after incubation with PK (Supplementary
Figure S1). In CJD type 2 and in further prion strains, however,
the PK cleavage site lies downstream the complete POM2 epitope,
thereby rendering PK-digested PrPSc ‘invisible’ to POM2 [16].
Pre-incubation of POM2-coupled beads with a peptide
corresponding to its epitope blocked immunoprecipitation of both
PrPC and PrPSc, providing evidence that POM2 binding occurs
through the PrP-specific pocket of the antibody and not by any
unspecific interactions (Figure 8B).
We then tested whether the POM2 epitope-mimicking peptide
could be used to compete for the binding of PrPC and PrPSc after it
is bound on the POM2-loaded beads. This could allow for specific
elution of the PrP isoforms and potentially other proteins
specifically binding to them. We repeated the immunoprecipita-
tion of PrPC and PrPSc with POM2, POM3 and POM6 and then
incubated the beads with excess amounts of POM2 or POM3
epitope-mimicking peptide. We found that the POM2 epitope
could efficiently elute PrPC and PrPSc from the POM2-coated
beads, but not from beads coated with POM3 or POM6
(Figure 8C, upper panel). Conversely, the POM3 epitope eluted
PrPC from POM3-coated beads, while only traces of PrPC and
PrPSc were detected in the eluates from POM2- or POM6- coated
beads, confirming the specificity of the elution protocol (Figure 8C,
lower panel).
Isolation of POM scFv
We went on to construct single chain antibodies (scFv) from
POM2, 11, 18 and 19 hybridoma cells with the goal to isolate and
sequence their heavy and light antibody chains. Moreover, the
scFv POMs enabled experiments to be performed for which IgGs
may not be optimal, such as immunohistochemistry, affinity
determinations and in vivo passive immunization experiments.
In order to isolate antigen-binding scFv of POM2, 11, 18 and
19, at least 3 rounds of panning were required and the sequences
of several good binders for each POM antibody were determined.
Based on phage ELISA results, the strongest binders were isolated
and used for subsequent expression and purification of POM scFv.
The absorbance values (above background) for the strongest
binders were: POM2=1.416, POM11= 0.654, POM18= 0.958
and POM19= 0.306. Although there were other clones that were
identified as strong antigen binders for each of the POMs, the
sequences for many of them were found to be similar (data not
shown), which was expected since the scFv genes were derived
from hybridoma (monoclonal) cells. An amino acid sequence
alignment comparison of the POM scFvs (the best binders) is
shown in Supplementary Figure S6. While the sequences are
similar, particularly for the N-terminal specific scFvs (POM2, 11
and 18), there are a number of amino acid differences in the
complementarity determining regions (CDR) as well as in the
flanking regions which may account for the differences in binding
properties of their original monoclonal antibodies.
Expression and purification of POM2 scFv
In order to characterize POM2 scFv in detail and compare the
properties of this recombinant antibody with its parent monoclo-
nal antibody, we overexpressed its cDNA in E. coli and purified the
recombinant scFv. The expression of POM2 scFv was found to be
almost exclusively within the insoluble inclusion bodies, which
necessitated the use of denaturing conditions during purification
followed by a refolding dialysis step. Supplementary Figure S6B
shows the results of the SDS-PAGE analysis of the purified POM2
scFv. There appears to be no contaminant protein bands visible in
the elution fraction lanes in the Coomassie Brilliant Blue R250-
stained 13% SDS-PAGE gel indicating a relatively high degree of
purity. During the refolding of the POM2 scFv, a large amount of
precipitation was observed and the degree of precipitation did not
appear to be affected by the concentration of POM2 scFv being
dialyzed. Despite the precipitation of scFv, the yield of refolded,
fully functional POM2 scFv was determined to be approximately
10–15mg/L of bacterial culture. The purified, refolded POM2
scFv was used in an ELISA with the N-terminal PrP peptide and it
was observed to be functional (data not shown). The functional
POM2 scFv was used in further studies aimed at characterizing
this scFv.
Affinity determination of selected POMs
In the last part of our study, we have adapted a previously
described methodology [22] that utilized SPR technology to
determine dissociation constants (KD) of selected antibodies. We
immobilized recombinant rmPrP121-231 (or BSA as negative
Figure 7. Immunohistochemistry on mouse brain for staining of PrPC. Consecutive brain sections of Tg20, WT, or Prnpo/o mice focusing near
the hippocampus area were incubated with the same concentration of each POM or IgG1 control antibody. The same HRP-conjugated anti-mouse
antibody was used for development, allowing direct comparison of the performance of each antibody. POM1 and POM19 seemed to be the most
sensitive antibodies in this assay, since they could readily detect PrPC in the wild-type brains.
doi:10.1371/journal.pone.0003872.g007
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control) on the chip surface through a covalent bond, making sure
that a low density PrP-covered plane is created (less than 1000
Resonance Units). We then injected POM19 at various increasing
concentrations, ranging from 420 pM to 110 nM, regenerating the
chip after each injection. We monitored the association and
dissociation behavior of each solution (Supplementary Figure S7A)
Figure 8. Immunoprecipitation, peptide competition and specific elution of PrPC and PrPSc with POMs. (A) Brain homogenates from
healthy or terminally scrapie sick mice were incubated with POM1–7, covalently coupled to paramagnetic beads. All antibodies tested
immunoprecipitated PrPC very efficiently and POM2, 5 and 6 showed competent immunoprecipitation of PK-digested PrPSc. Plasminogen was used as
a positive and non-specific IgG as a negative control. (B) Brain homogenates from healthy or terminally scrapie sick mice were mixed with POM2-,
POM3- or POM6-coupled beads, which were pre-incubated with a peptide corresponding to the epitopes of POM2 (QPHGGGW) or POM3 (HNQWNK)
or without any peptide for comparison. Pre-incubation of POM2-coupled beads with its epitope blocked immunoprecipitation of both PrPC and PrPSc,
whereas same amounts of an unrelated peptide (POM3-epitope) had no effect on the binding. Similarly, immunoprecipitation of PrPC by POM3 was
only blocked by its corresponding peptide-epitope and not by the epitope of POM2. As expected none of the peptides interfered with binding of
POM6 which interacts with the C-terminal part of PrP. SCR: scrapie. (C) PrPC and PrPSc can be eluted from POM2-coupled beads after incubation with
excess amounts of POM2 – but not POM2 – peptide epitope. Conversely PrPC is found in the eluates of POM3-coupled beads when they are
incubated with POM3 – but not POM2 – peptide epitope. Eluates from POM6-coupled beads show only trace amounts of both PrP isoforms. All
membranes were immunoblotted with biotinylated POM1 and HRP-labeled avidin.
doi:10.1371/journal.pone.0003872.g008
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and we fitted the curves using algorithms available in the
BIAevaluation 4.1 software. Based on these measurements, we
have calculated that the binding constant of POM19 is 870 pM.
Following a similar procedure we found the binding constant of
POM1 to be 580 pM (data not shown).
When we followed the same protocol to calculate the affinities of
the octarepeat-specific antibodies, however, we did not obtain
curves that could fit in any of the available models of the
BIAevaluation software. This was probably due to the fact that the
reaction stoichiometry became increasingly complex, since we
tested the binding of the bivalent IgG (POM2 or POM12)
antibody to the tetravalent rmPrP23-231 – since the POM2 and
POM12 epitope occurs four times in the PrP sequence. In order to
overcome this obstacle, we attempted to calculate the equilibrium
dissociation constants with competition BIAcore [23]. In this
method, the BIAcore is used merely as a sensitive instrument to
measure free antibody concentrations. Using a panel of solutions
of defined antibody concentrations – ranging from 12nM-125pM
– we first created a standard curve of POM2 IgG (data not shown)
or scFv (Supplementary Figure S7B). We then prepared a 6nM
POM2 scFv solution and mixed it with a series of defined
concentrations of the epitope-mimicking peptide (13 different
concentrations, ranging from 100-0.01nM). The solutions were
allowed to reach equilibrium and then the concentration of free
scFv POM2 in each tube was measured by BIAcore. We plotted
the values of free antibody against those of the peptide competitor
using the BIAevaluation software (Supplementary Figure S7C).
This allowed for an estimation of the single binding event of the
two monovalent reagents, scFv POM2 to the singular peptide
epitope, is 20nM.
The actual binding of the bivalent IgG POM2, however, is a
result of the cooperative interaction of each paratope of the IgG
molecule with two – either consecutive or intermittent – epitope
stretches within the octarepeat region of PrP. This translates in an
apparent binding strength that is much higher and is the most
probable reason why POM2 and POM12 are among the most
sensitive antibodies of our series in most assays tested. In an
attempt to determine the avidity of the reaction: POM2+2PrP R
POM2PrP2 through theoretical calculations, we assumed that the
two sub-reactions POM2+PrP R POM2PrP and POM2PrP+PrP
R POM2PrP2 are defined by equal KD. This assumption allows
for a simple calculation of the avidity of the total one-to-two
reaction as follows: if KD1=KD2=KD, then KDtotal =
KD
2= (2*1028)2 = 4*10216M2.
Discussion
Here, we report the production and detailed characterization of
a panel of monoclonal antibodies against PrP, designated POM1–
POM19. These antibodies were raised against recombinant mouse
rmPrP23-231 in PrP-deficient (Prnp
o/o) mice and selected for binding
to both denatured PrP in Western Blot (Supplementary Figure S1)
and native, cell-bound PrPC by flow cytometry and ELISA
(Supplementary Figure S2).
We had little success in mapping the epitopes of the POM
antibodies using linear short peptide arrays. We could, however,
identify the epitopes of all antibodies that bind within the first 100
amino acids of PrP by peptide competition ELISA. We found
these data to be more informative, since they could automatically
be translated into a tool for testing the binding specificity of
immunoprecipitation results and other assays (Figure 8B).
Additionally, the competing peptides could be used as specific
elution reagents for PrPC and PrPSc (Figure 8C). This is extremely
useful since it has recently been found that, due to the
hydrophobic nature of exposed regions of PrPSc, the specificity
of immunoprecipitation reactions should be treated with caution
[21]. Our results provide a method that allows for a direct test for
specificity of PrPC and PrPSc immunoprecipitation, as well as for
specific elution of both isoforms and their interacting partners.
While the physiological role of PrPC and the toxic mechanism of
PrPSc remain mysterious, future proteomic analysis of such
specific, PrP-containing eluates may shed some light on these
important issues.
Why were no peptide competitors found for any of the
antibodies interacting with the globular domain of the PrP
molecule? This unexpected result was most likely due to these
antibodies recognizing discontinuous or conformational epitopes.
The latter hypothesis is not formally excluded, but seems highly
unlikely since all POM antibodies recognized PrP on Western
blots under denaturing conditions. Although under western
blotting conditions proteins are denatured prior to transferring
to a membrane, refolding of the protein and of ‘conformational’
antibody epitopes on the membrane can occur. The reactivity of a
monoclonal antibody in a western blot format does therefore not
definitively exclude its reactivity with a structured epitope.
Only a small fraction of monoclonal antibodies can be mapped
with linear peptides, whereas most antibodies are best mapped
using mutant or truncated versions of the antigen. In our analysis,
indirect information about the binding sites of some of our
antibodies was gained through this approach (Figure 5 and S4).
For example POM4, 10, and 19 were found to bind a
discontinuous epitope consisting of a very C-terminal part of the
protein (around amino acids 220) and a middle part of the protein
at amino acids 121–134. The latter was indentified, because these
three antibodies did not bind – or their binding was significantly
reduced – to an N-terminally truncated PrP variant (DF) with a
deletion of amino acids 33–134, while it still bound to another
variant (DE) with a shorter deletion of residues 33–121
(Supplementary Figure S4B). It remains unclear whether amino
acids 121–134 are actively participating in the binding to POM4,
10, and 19, or if the deletion of this part induces a conformational
change in the distant C-terminal part, which is certainly essential
for the antibody-antigen interaction. Another possibility that we
cannot formally exclude is that due to deletion of amino acids 33–
134, DF is differentially glycosylated with a glycan chain that
interferes with the epitope of these three POMs.
It is interesting that POM5, which was mapped to a loop region
preceding the second a-helix of the globular domain of PrPC
(Figure 6), seems to immunoprecipitate PrPSc only after PK
digestion (Figure 8A). This observation suggests that the POM5
loop epitope is potentially exposed on PrPSc only after truncation
of the N-terminal part of the protein or, in other words, it is
masked in the full-length PrPSc molecule.
Two of the N-terminal antibodies (POM2 and POM12)
recognize four repetitive epitopes in the PrP sequence. Conse-
quently, we could demonstrate that two antibody molecules can
simultaneously bind one PrP molecule (Supplementary Figure
S3B) [16]. Although we have not formally shown that the two
binding sites of one IgG molecule of POM2 or POM12 attach
concurrently to two epitope stretches within the octarepeat region
of PrP, this represents the most plausible scenario. If this is indeed
true, then the actual binding of the bivalent IgG POM2 and
POM12 will be the result of this cooperative interaction. This
property could well explain the fact that these two antibodies have
consistently been among the most sensitive ones within our
collection, despite the fact that the measured affinity of a single
binding event of a monovalent POM2 (scFv) and the singular
peptide epitope is only 20nM.
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In conclusion, we present a new panel of high affinity
monoclonal anti-PrP antibodies with specificities in diverse sites
within the prion protein. With their comprehensive characteriza-
tion in a variety of techniques, including western blotting, ELISA,
flow cytometry, immunoprecipitation, immunohistochemistry and
surface plasmon resonance, we think that the POMs are a very
useful tool for prion research and diagnosis.
Materials and Methods
Antigen
Recombinant mouse PrP was produced in bacteria and purified
as described in [24,25]. Briefly, competent bacteria were
transfected with a plasmid (pRSETA, Invitrogen) expressing N-
terminally tagged (6 histidines) mouse PrP, either full length
spanning amino acids 23–231 (rmPrP23-231) or N-terminally
truncated, amino acids 121–231 (rmPrP121-231). PrP-expressing
bacteria were grown until an OD of 1.0 was reached (6L of culture
in LB) and protein expression was induced using isopropyl-beta-D-
thiogalactopyranoside (IPTG). Bacteria were left to grow for
another 5–7hrs and then harvested. Cells were resuspended in 6M
Guanidium Hydrochloride, sonicated and centrifuged. The
supernatant was run over a Ni-NTA column, which captures the
6his-tag attached to the N-terminus of PrP. A gradient buffer with
a decreasing concentration of denaturing agent was passed over
the immobilized PrP for refolding. Renatured PrP was then eluted
using imidazole, which competes for the binding to Ni. The 6his-
tag was removed by thrombin cleavage. Finally, the protein
concentration was determined by its absorbance at 280nm and the
purity after purification was checked by SDS-PAGE stained with
Coomassie.
Immunization
Prnpo/o mice were immunized with recombinant rmPrP23-231.
For the initial injection, 10 mg of protein was emulsified in
complete Freund’s adjuvant (CFA). Boosting injections of 10–
20 mg of protein subcutaneous (s.c.) or intravenous (i.v.) followed
over a period of 65 days, according to the following schedule:
Day 1: s.c. injection of 10 mg rmPrP23-231+CFA, Day 22: s.c.
injection of 10 mg rmPrP23-231, Day 43: s.c. injection of 20 mg
rmPrP23-231, Day 64: i.v. injection of 10 mg rmPrP23-231, Day 65:
i.v. injection of 10 mg rmPrP23-231, Day 66: i.v. injection of 10 mg
rmPrP23-231, Day 66: Fusion.
Fusion
After immunization, mice were sacrificed and spleen cells were
isolated and fused with the immortalized myeloma cell line Sp2/0-
Ag14 with polyethylene glycol (PEG) using a standard fusion
protocol. The selection was made with HAT medium (Hypoxan-
thine, Aminopterin, Thymidine). Clones consisting of a small
number of cells were transferred in fresh wells and cultured. Based
on a first screen of 55 positive clones, 19 most interesting clones
were selected for further characterization, hereafter termed
POM1–19.
Antibody purification
A standard antibody purification protocol was used (by
GENOVAC GmbH, Germany). In brief, hybridoma cells were
cultured to a log-phase state. During early scale up, standard FCS
was step-wise exchanged with an ultra-low-IgG FCS while they
were intensively checked for proliferation and viability. After
scaling up, cells were transferred into a production flask in high
density and then kept in static culture for a given period.
Supernatant was harvested, centrifuged and filtered. Affinity
purification was performed by binding to a Protein-G column
followed by elution of the bound antibody with glycine buffer
(pH=3.0) and subsequent dialysis against PBS (pH7.2–7.4). Purity
was checked by SDS-PAGE and protein concentration was
determined by Lowry assay.
Western Blotting
Equal amounts of recombinant prion proteins (100ng for
Figure 5A and 10ng for Figure 5C) were mixed with loading
dye and loaded on a 12% NuPAGE gel (Invitrogen, running with
MES buffer). Mouse brain homogenates were prepared in PBS,
0.05% sodium deoxycholate, and 0.05% Nonidet P-40. For PK
digestion 25 mg/ml of enzyme was used to digest PrPC. Samples
corresponding to 40 mg of total proteins (with or without prior PK
digestion) were mixed with loading dye and loaded on a 12%
NuPAGE gel. Proteins were then transferred onto a nitrocellulose
membrane incubated with hybridoma cell supernatant or purified
monoclonal anti-PrP antibodies and horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse IgG (gamma) antibody
(Zymed). For analysis of samples acquired from immunoprecip-
itation, blots were incubated with a biotinylated anti-PrP (POM1)
antibody and HRP-labeled avidin (Pharmingen). Blots were finally
incubated with HRP substrate (ECL, Pierce) and exposed on
photosensitive film (Kodak) or with Versadoc 3000 imaging system
(Bio-Rad).
Anti-Native PrPC Antibody Titer Determination
Splenocytes or blood cells derived from transgenic tg33 mice
overexpressing PrPC on T cells (Raeber et al., 1999b) were
incubated with hybridoma cell supernatant of the novel mono-
clonal anti-PrP antibodies or with monoclonal anti-PrP antibody
6H4 (Prionics). Cells were washed and incubated with a FITC-
labeled anti-mouse IgG secondary antibody or FITC-labeled anti-
mouse IgM secondary antibody (Caltag Laboratories, Naenikon,
Switzerland). Thereafter, cells were stained with phycoerythrin
(PE)-labeled anti-Thy 1.2 for detecting T cells. All antibodies were
obtained from Becton Dickinson unless otherwise indicated. Lysis
of red blood cells was performed with FACS lysing solution
(Becton Dickinson). Living cells were gated by using a combination
of forward scatter and side scatter. Data were acquired on a FACS
Calibur (Becton Dickinson) with CELLQUEST software (Becton
Dickinson); post-acquisition analyses were performed with Win-
dows Multiple Document Interface (WINMDI, version 2.8;
http://facs.scripps.edu/).
Peptides
Mouse PrP-peptide libraries were synthesized by Jerini,
Germany. The first one consisted of 100 peptides, spanning the
whole mature mouse PrP sequence. Each peptide was 12 amino
acids long and their PrP-sequences were shifted by two amino
acids each. The second one consisted of 25-mers, shifted by 5
amino acids each and spanned amino acids 111–225 of the mature
mouse PrP sequence. As a control, a 25-mer containing a part of
the octarepeat region – amino acids 65–89 – was used.
ELISA
a. Direct ELISA against rmPrP for screening positive
clones and for isotyping. Plates were coated at 4uC overnight
with 5 mg/ml recombinant mouse PrP (either rmPrP23-231 or
rmPrP121-231) diluted in PBS and were washed with PBS
containing 0.1% (vol/vol) Tween-20 (PBST) They were blocked
with 5% BSA and were then incubated for 2hrs at room
temperature with 30 ml of 2-fold serially diluted hybridoma cell
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supernatant (1:10 prediluted) in PBST containing 1–5% BSA.
Plates were washed thoroughly with PBST and then probed with a
horseradish peroxidase-conjugated anti-mouse antibody (total
IgG, or isotype specific antibodies IgM, IgG1, IgG2a, IgG2b,
IgG3 all from Zymed, used at 1:1,000 dilution in 5% BSA, PBST).
After washing, plates were developed with 2.2-azino-diethyl-
benzothiazolinsulfonate, and optical density was measured at
405nm. Titer was defined as the highest dilution showing an OD
more than two times the technical background, which was
calculated as the average of uncoated wells and wells incubated
without serum.
b. Competition ELISA for epitope mapping. 384-well
plates were coated with 300ng/ml rmPrP23-231 overnight at 4uC.
Plates were washed with PBS containing 0.1% (vol/vol) Tween 20
(PBST), and blocked with 5% BSA for 2hrs at room temperature.
After washing, plates were incubated with 30 ml of 2-fold serially
diluted hybridoma cell supernatant (prediluted accordingly
1:1000–1:5000) in PBST containing 1% BSA with or without
peptides in a final concentration of 0.8–8ng/ml. After 2hrs at
room temperature, plates were washed 4 times and then probed
with horseradish peroxidase conjugated rabbit anti-mouse IgG
(1:000 dilution, Zymed) for 1hr at room temperature. Plates were
developed with 2.2-azino-diethyl-benzothiazolinsulfonate, and
optical density was measured at 405nm. Titer was defined as the
highest dilution showing an OD more than two times the technical
background, which was calculated as the average of uncoated wells
and wells incubated without serum.
c. Sandwich ELISA with biotinylated mAbs. 96-well plates
were coated with 400ng/ml of purified antibodies (designated
POM1, 2, 3, 4 and 9) overnight at 4uC. Plates were washed with
PBS containing 0.1% (vol/vol) Tween 20 (PBST), and blocked
with 5% BSA for 2hrs at room temperature. After washing, plates
were incubated with 50 ml of 2-fold serially diluted rmPrP23-231 in
PBST containing 1% BSA, starting from a 100ng/ml dilution.
After 1hr at room temperature, plates were washed extensively
and then probed with biotinylated POMs at a concentration of
200ng/ml in PBST containing 1% BSA, for 1hr at room
temperature. Subsequently, after washing, plates were incubated
with horseradish peroxidase conjugated Avidin (1:5000 dilution,
Invitrogen) for 1hr at room temperature. Plates were developed
with 2.2-azino-diethyl-benzothiazolinsulfonate (Boehringer), and
optical density was measured at 405nm. Titer was defined as the
highest dilution showing an OD more than two times the technical
background, which was calculated as the average of uncoated wells
and wells incubated without serum.
SPR measurements
All experiments were performed with BIAcore3000 (Functional
Genomics Center Zurich, FGCZ).
a. Pair wise mapping. Anti-PrP mAbs (POMs) or IgG1 for
isotype control were immobilized on CM-5 chips (BIAcore) after
7 minute activation with NHS/EDC at a flow rate of 5 ml/min.
5 ml of a 50 mg/ml antibody solution in sodium acetate buffer
pH=4.5, were used to immobilize approximately 2500–5000
response units of covalently bound antibody. After inactivation of
the surface with ethanolamine the surface was washed twice with
SDS 0.5% (20 ml) to remove any non-covalently bound antibody.
The system was primed and then a new sensogram was started
with HBS-EP (BIAcore) as running buffer. 20 ml were used for all
injections at a constant flow rate at 5 ml/min. Recombinant
proteins or POM antibodies were injected on the chip (BSA or
PrP) at a concentration of 50 mg/ml diluted in HBS-EP buffer. For
regeneration of the chip several injections of SDS 0.5% (BIAcore)
are needed until the baseline returns to 0. For control the
injections were made to flow cells 1 and 2 or 3 and 4, where the
first flow cell was coated with control IgG1 (Zymed) antibody and
the second with each POM antibody.
b. Affinity measurements. BSA and rmPrP121-231 were
covalently captured on flow cells 1 and 2 respectively of a CM5
chip (BIAcore) after activation with NHS/EDC at a flow rate of
5 ml/min. 5 ml of a 50 mg/ml antibody solution in sodium acetate
buffer pH=4.5, were used to immobilize approximately 1000
response units of covalently bound protein. After inactivation of the
surface with ethanolamine, the system was primed and then a new
sensogram was started with HBS-EP (BIAcore) as running buffer.
Antibodies were injected at a constant flow rate of 20 ml/min. All
antibodies were diluted in HBS-EP buffer (BIAcore) in the following
concentrations: 110nM, 54nM, 27nM, 13nM, 6.8nM, 3.4nM,
1.7nM, 850pM and 420pM. After the end of each injection,
antibodies were allowed to dissociate for 20min (1200sec) and then
the chip was regenerated with 100mM HCl (BIAcore). Sensograms
in Supplementary Figure S7 represent changes in resonance units
on flow cell immobilized with PrP, after subtraction of changes in
resonance units on control flow cells (BSA).
For the equilibrium dissociation constant calculation with
competition BIAcore, we first coupled a control (scrambled) or
the POM2 epitope mimicking on flow cells 1 and 2 respectively of
a CM5 chip (BIAcore) after activation with NHS/EDC as describe
before. We then injected POM2 IgG (or scFv) diluted in HBS-EP
buffer in the following concentrations: 12nM, 6nM, 4nM, 2nM,
1nm, 500pM, 250pM, 125pM and 0nM, with 100mM HCl after
each concentration for regeneration. Each concentration was
injected twice and the slope of the RU increase in the middle of
each injection was used for creating the standard curve. We then
prepared a 6nM POM2 scFv solution and mixed it with 13
different concentrations of the epitope-mimicking peptide, ranging
from 100-0.01nM. The solutions were allowed to reach equilib-
rium at room temperature for 1hr and then concentration of free
scFv POM2 in each tube was measured by BIAcore.
Immunohistochemistry
Paraffin-fixed (1–2 mm) consecutive sections of mouse brains
were deparaffinized by serial submersion in Xylene (365min),
100% ethanol (362min), 96% ethanol (363min) 70% ethanol
(3min), distilled H2O and PBS. They were then submerged in
citrate buffer (1.8mM Citric acid and 8.2mM Sodium citrate,
pH=10.6) and subjected to high pressure for 10min using a steam
cooker. Samples were then allowed to cool down for 10min and
then washed in PBS. They were then incubated for 10min in 3%
H2O2 (in PBS) and washed in PBS. Slides were blocked for 1hr at
room temperature (RT) with TNB buffer (0.10M Tris-HCl, 0.15M
NaCl, pH=7.5 with blocking reagent, Perkin Elmer) and then
incubated at 4uC overnight with purified POM antibodies (2mg/
ml, stock solutions) diluted 1:500 on TNB. The next day, slides
were washed with PBS and then incubated with an HRP-
conjugated anti-mouse IgG antibody (Zymed) (1:100 of 1mg/ml
stock solution in TNB). After washing, slides were stained with a
chromogenic HRP substrate AEC (DAKO) for approximately
20min at RT. Nuclear stain was performed with hematoxylin.
Immunoprecipitation
Dynal tosylactivated M450 beads (Dynal No. 140.04) were
covalently coupled with purified POM antibodies and M280 for
plasminogen (Dynal No. 140.03). For the coupling reaction,
500 ml of beads were extensively washed in PBS and then
resuspended in 1ml of coupling buffer (0.1M boric acid, pH=9.5).
100 mg of purified Plasminogen or POM antibodies were added
and the coupling reaction was performed with stark agitation at
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37uC for 16hrs. After washing in PBS with 0.1% BSA, the reaction
was stopped by incubating in 1ml of blocking buffer (0.2M Tris-
HCl, pH=8.5 with 0.1% w/v BSA) for 6hrs. 50 mg of brain
proteins were diluted in 1ml of PAA buffer (PBS with 3%NP-40
and 3%Tween.20) with 206 protease inhibitors (Complete mini,
Roche) and added on washed and magnetically collected beads
without any liquid (corresponding to 10 mg of antibody coupled to
50 ml of beads). Beads were incubated with tilt rotation for 2hrs at
RT and then washed extensively with PAA buffer. For the
competition experiment, POM2, POM3 or POM6-coupled beads
(corresponding to 5 mg of antibody coupled to 25 ml of beads) were
preincubated for 1hr in RT with 1ml PAA with or without 40 mg/
ml of peptides: QPHGGGW, for POM2 epitope or HNQWNK
for POM3 epitope (negative control). Subsequently, 25 mg of brain
proteins were added and incubated for 1hr at RT with rotation.
Washed and magnetically collected beads were mixed with 20 ml
of SDS-loading buffer. 10–30 ml of the protein solutions were used
for western blot analysis.
Construction, expression and purification of POM scFvs
a. Amplification and linking of VL and VH
domains. RNA from each of the POM hybridomas (POM2,
11, 18, and 19) was diluted to 0.1 mg/ml and heated at 65uC for
10 minutes. After cooling the RNA samples on ice, 20 mL of each
sample was used as a template for first strand complementary
DNA (cDNA) synthesis using the First Strand cDNA synthesis kit
(GE Healthcare Life Sciences, QC, Canada) according to the
manufacturer’s recommended procedure. The cDNA (5 ml) was
used as a template for the polymerase chain reaction (PCR)
amplification of the variable light (VL) and variable heavy (VH)
antibody domains as described by [26] with modifications. The
primers used to amplify the variable domains are listed below and
were designed to allow for the incorporation of the scFv genes into
the SfiI restriction enzyme sites of the pAK100 and pJB12 phage
display vectors kindly supplied by Dr. Andreas Pluckthun,
University of Zurich, Switzerland [27]. PCR reactions contained
150 mM dNTPs, 1.5mM Mg2+, Platinum Taq DNA polymerase
(Invitrogen, ON, Canada) and reaction buffer used in the Expand
High Fidelity PCR system (Roche Applied Science, QC, Canada).
PCR products were analyzed by agarose gel electrophoresis and
the amplified DNA was gel purified using the QIAEXII gel
extraction kit (Qiagen, ON, Canada) according to the
manufacturer’s recommended procedure. A second round of
PCR was performed in order to link the amplified VL and VH
domains by splicing by overlap extension (SOE). This was
accomplished by using 10ng of the VL and VH PCR products
along with the ‘scforward’ and ‘scback’ primers (see below) in a
PCR reaction using the same cycles and reaction conditions as
before. The PCR products were analyzed by agarose gel
electrophoresis and the scFv DNA (approximately 750 bp) was
excised and gel purified as before.
b. Primers for PCR amplification of VL and VH
domains. The listed sequences are written in the 59 to 39
direction and are provided using the IUPAC nomenclature of
mixed bases (R=A or G, M=A or C, Y=C or T, K=G or T,
S=C or G, W=A or T, H=A or C or T, B=C or G or T, V=A
or C or G and D=A or G or T.)
Heavy chain forward primers:
HF1: GGAATTCGGCCCCCGAGGCCGAGGAAACGGT-
GACCGTGGT
HF2: GGAATTCGGCCCCCGAGGCCGAGGAGACTGT-
GAGAGTGGT
HF3: GGAATTCGGCCCCCGAGGCCGCAGAGACAGT-
GACCAGAGT
HF4: GGAATTCGGCCCCCGAGGCCGAGGAGACGGT-
GACTGAGGT
Heavy chain reverse primers:
HB1: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAKGTRMAGCTTCAGGAGTC
HB2: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTBCAGCTGCAGCAGTC
HB39: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTGCAGCTGAAGSARTC
HB4: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTCCARCTGCAACARTC
HB5: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTYCAGCTBCAGCARTC
HB69: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTYCARCTGCAGCARTC
HB79: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTCCACGTGAAGCARTC
HB89: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTGAASSTGGTGGARTC
HB99: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAVGTGAWGSTGGTGGAGTC
HB109: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTGCAGSTGGTGGARTC
HB119: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAKGTGCAMCTGGTGGARTC
HB12: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTGAAGCTGATGGARTC
HB139: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTGCARCTTGTTGARTC
HB149: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GARGTRAAGCTTCTCGARTC
HB159: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAAGTGAARSTTGAGGARTC
HB169: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTTACTCTRAAASARTC
HB17: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
CAGGTCCAACTVCAGCARCC
HB189: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GATGTGAACTTGGAASARTC
HB199: GGCGGCGGCGGCTCCGGTGGTGGTGGATCC-
GAGGTGAAGGTCATCGARTC
Light chain forward primers:
LF19: GGAGCCGCCGCCGCC(AGAACCACCACCACC)2A-
CGTTTKATTTCCAGCTTGG
LF4: GGAGCCGCCGCCGCC(AGAACCACCACCACC)2A-
CGTTTTATTTCCAACTTTG
LF5: GGAGCCGCCGCCGCC(AGAACCACCACCACC)2A-
CGTTTCAGCTCCAGCTTGG
LFl: GGAGCCGCCGCCGCC(AGAACCACCACCACC)2A-
CCTAGGACAGTCAGTTTGG
Light chain reverse primers:
LB1: GCCATGGCGGACTACAAAGAYATCCAGCTGACT-
CAGCC
LB2: GCCATGGCGGACTACAAAGAYATTGTTCTCWCC-
CAGTC
LB3: GCCATGGCGGACTACAAAGAYATTGTGMTMAC-
TCAGTC
LB4: GCCATGGCGGACTACAAAGAYATTGTGYTRACA-
CAGTC
LB5: GCCATGGCGGACTACAAAGAYATTGTRATGAC-
MCAGTC
LB6: GCCATGGCGGACTACAAAGAYATTMAGATRAM-
CCAGTC
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LB7: GCCATGGCGGACTACAAAGAYATTCAGATGAYD-
CAGTC
LB8: GCCATGGCGGACTACAAAGAYATYCAGATGACA-
CAGAC
LB9: GCCATGGCGGACTACAAAGAYATTGTTCTCAWC-
CAGTC
LB10: GCCATGGCGGACTACAAAGAYATTGWGCTSAC-
CCAATC
LB11: GCCATGGCGGACTACAAAGAYATTSTRATGAC-
CCARTC
LB12: GCCATGGCGGACTACAAAGAYRTTKTGATGAC-
CCARAC
LB13: GCCATGGCGGACTACAAAGAYATTGTGATGAC-
BCAGKC
LB14: GCCATGGCGGACTACAAAGAYATTGTGATAAC-
YCAGGA
LB15: GCCATGGCGGACTACAAAGAYATTGTGATGAC-
CCAGWT
LB16: GCCATGGCGGACTACAAAGAYATTGTGATGAC-
ACAACC
LB17: GCCATGGCGGACTACAAAGAYATTTTGCTGAC-
TCAGTC
LBl: GCCATGGCGGACTACAAAGATGCTGTTGTGAC-
TCAGGAATC
scforward primer:
GGAATTCGGCCCCCGAG
scback primer:
TTACTCGCGGCCCAGCCGGCCATGGCGGACTACA-
AAG
c. Cloning of scFv genes into phage display vectors. The
PCR-amplified genes encoding scFvs for POM2, 11, 18, and 19
along with the pAK100 and pJB12 phage display vectors were
digested with the SfiI restriction enzyme (New England Biolabs,
ON, Canada) at 50uC overnight. The digested products were
analyzed by agarose gel electrophoresis and gel purified as before.
The gel purified digested scFv genes were ligated to the digested
phage display vectors using the Rapid DNA ligation kit (Roche)
according to the manufacturer’s instructions. Competent TG1 E.
coli cells (500 ml) were mixed with the ligation mixes (10–15 ml) and
the solutions were incubated on ice for 45 minutes and then heat
shocked in a 42uC waterbath for 2 minutes after which the
samples were immediately placed on ice for 2 minutes. The cells
were incubated in a 37uC shaker (250rpm) for 1 hour and then
plated onto 2X YT agar plates supplemented with 1% (w/v)
glucose and 30 mg/mL chloramphenicol. The plates were
incubated at 37uC overnight to allow the growth of transformed
cells.
d. Phage rescue and panning for isolation of antigen
binders. The colonies (transformants) were resuspended in 5ml
of 2X YT media supplemented with 1% glucose and 30 mg/
mlchloramphenicol (2X YT-GC). Fresh 2X YT-GC media (5ml)
was inoculated with 50 ml of resuspended colonies and the culture
was incubated at 37uC at 250 rpm until the OD600nm of the
cultures was approximately 0.5. At this point, 5ml of fresh 2X YT-
GC media containing 1mM IPTG and 16109 cfu VCSM13
helper phage (Stratagene, CA, USA) was added to the cultures,
which were incubated overnight at 26uC with shaking (250rpm).
The cultures were centrifuged (10006g, 20 minutes, 22uC) and
the supernatants containing the phage were collected. The
supernatants containing the scFv-displaying phage were mixed
with 2ml sterile PEG/NaCl solution (20% w/v PEG 8000 and
14.6% w/v NaCl), vortexed briefly and incubated on ice for
1 hour to precipitate them. The precipitated phage was collected
by centrifugation (10,0006g, 20 minutes, 4uC) followed by the
removal of the supernatant. The phage pellets were resuspended in
500 ml PBS containing BSA (2% w/v) and subsequently used to
pan for the isolation of antigen binders as described below.
Wells of the ReactiBind Streptavidin-coated pre-blocked clear
strip plates (Pierce, ON, Canada) were coated with 100 ml/well of
10 mg/ml biotinylated N-terminal peptide corresponding to
residues 64–88 of the mouse PrP sequence
(WGQPHGGSWGQPHGGSWGQPHGGGW) in PBS, pH=7
for POM2, 11, and 18 and biotinylated C-terminal peptide
corresponding to residues 202–226 (VKMMERVVEQMCVT-
QYQKESQAYYD) for POM19. PBS (100 ml/well) without the
peptides was added to other wells to serve as uncoated controls.
The plates were incubated at 22uC for 2 hours with agitation and
then each well was washed 3 times with PBS. The phage
suspension (100 ml/well) was added to the wells and the plates
were incubated at 22uC for 2 hours with agitation. The plates
were washed 20 times with sterile PBS containing 0.05% (v/v)
Tween-20 followed by 20 additional washes with sterile PBS. The
bound phage particles were eluted by the addition of sodium
acetate buffer (100 ml; 0.1M acetic acid, 0.15M NaCl, pH=2.8)
and incubation for 8 minutes followed by neutralization with 12 ml
2M Tris buffer, pH=9.5. The neutralized phage solutions were
used immediately to infect 5ml log-phase TG1 E. coli cells
(OD600nm ,0.5) for 30 minutes at 37uC followed by an additional
30 minutes at 22uC. The bacterial solutions were centrifuged
(10006g, 5 minutes, 4uC), 4ml of the supernatants were removed
and the bacterial pellets were resuspended in the remaining liquid.
The cells were spread evenly onto 2X YT-GC agar plates, which
were incubated at 30uC overnight. The colonies were either used
in a phage ELISA (see below) to identify antigen binders or they
were pooled and used in another round of panning. 3–5 rounds of
panning with decreasing concentrations of coating peptide in each
round were usually required to isolate strong antigen binders.
e. Phage ELISA. After each round of panning, randomly
selected colonies were used to inoculate separate 5ml of 2X YT-
GC media. The cultures were incubated at 37uC, 250rpm until
OD600nm ,0.5. Fresh 2X YT-GC media (5ml) supplemented with
1mM IPTG and 16109 cfu VCSM13 helper phage was added to
each culture, which were then incubated overnight at 26–28uC,
250 rpm. The cultures were centrifuged (10006g, 20min, 22uC)
and the supernatants were added to separate 2ml of sterile PEG/
NaCl to precipitate the phage. After vortexing, the samples were
incubated on ice for 1 hour and then centrifuged (10,0006g,
20min, 4uC). The supernatants were discarded and the pellets
were resuspended in 200 ml PBS containing BSA (2% w/v).
ReactiBind Streptavidin-coated pre-blocked clear strip plates were
coated with the appropriate peptide, incubated and washed with
PBS as described above. Phage suspensions (100 ml/well) were
added to the wells (coated and uncoated) and the plates were
incubated at 22uC for 2 hours with agitation. The wells were
washed 5 times with PBS containing 0.05% (v/v) Tween-20
followed by 6 times with PBS alone. 100 ml HRP/anti-M13
monoclonal conjugate diluted 1:2500 (GE Healthcare Life
Sciences) in PBS containing BSA (2% w/v) was added to each
of the wells and the plates were incubated at 22uC for 1 hour with
agitation. The wells were washed with PBS-Tween-20 and PBS
alone as described above and then 100 ml of SureBlue Reserve
TMB Microwell Peroxidase Substrate (KPL, MD, USA) was
added to each well. The reaction was stopped by the addition of
1N HCl (100 ml/well) when satisfied with the color intensity and
the absorbance was measured at 450nm. Clones were identified as
strong antigen binders if the absorbance was at least $0.2 and at
least$2 times the background. The DNA sequence for each of the
strong antigen binders was determined and the corresponding
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amino acid sequences were aligned to identify differences in the
sequences.
f. Expression and purification of POM2 scFv. The POM2
scFv gene for the strongest binder was subcloned into the bacterial
expression vector pET30a (Novagen, WI, USA) at the NdeI and XhoI
restriction enzyme sites of the multiple cloning site. Competent
Rosetta (DE3) pLysS E.coli cells (Novagen) were transformed with
the POM2 scFv-pET30a construct and used for bacterial
overexpression for subsequent scFv purification. 150ml Luria-
Bertani (LB) media containing 50 mg/ml kanamycin and 30 mg/ml
chloramphenicol (LB-KC) was inoculated with a single colony of the
transformed Rosetta (DE3) pLysS E.coli. The culture was incubated
overnight at 37uC, 250rpm and 50ml of the overnight culture was
used to inoculate 1L fresh LB-KC. The culture was incubated at
37uC, 250rpm until OD600nm 0.4–0.6. IPTG (1mM final
concentration) was added to the bacterial culture, which was then
incubated overnight at 22uC, 250rpm or 3 hours at 37uC, 250rpm.
The culture was centrifuged (15,0006g, 15min, 4uC) and the pellet
resuspended in (30ml/L of culture) Buffer#1 (50mM
NaH2PO4?H2O, 300mM NaCl, pH=7.0). The sample was
sonicated on ice to lyse cells and then centrifuged (15,0006g,
15 minutes, 4uC). Due to the expression of the POM2 scFv in the
insoluble inclusion bodies, the supernatant was discarded and the
pellet was resuspended in (30ml/L of culture) Buffer#2 (100mM
NaH2PO4?H2O, 10mM Tris-HCl, 8M urea, 5mM imidazole,
5mM b-mercaptoethanol, pH=8.0). The sample was stirred at
22uC for 1 hour and then centrifuged (10,0006g, 10min, 4uC). The
supernatant was collected and added to (30ml/L culture) Ni-NTA
agarose (Qiagen), which had been equilibrated with at least 10
column volumes of Buffer#2. After collecting the flow-through, the
Ni-NTA agarose was washed first with approximately 5 column
volumes of Wash Buffer#1 (100mM NaH2PO4?H2O, 10mM Tris-
HCl, 8M urea, 10mM imidazole, pH=8.0) and then with Wash
Buffer#2 (100mM NaH2PO4?H2O, 10mM Tris-HCl, 8M urea,
250mM imidazole, pH=8.0). The Wash Buffer#2 eluate
containing POM2 scFv was collected in 40ml fractions and then
analyzed by gel electrophoresis in a 13% SDS-PAGE gel stained
with Coomassie Brilliant Blue R250 (Sigma-Aldrich, ON, Canada).
To resolubilize the denatured purified POM2 scFv, the collected
samples were dialyzed against 5mMTris-HCl, pH=7.5 at 4uC over
48 hours with multiple changes of dialysis buffer. The soluble
POM2 scFv was lyophilized to concentrate and then resuspended in
sterilized water to the desired protein concentration for subsequent
experiments.
Supporting Information
Figure S1 First screen and selection of best performing clones.
Western Blot analysis of membrane strips containing PK-digested
brain homogenate from terminally sick scrapie mice, using all 55
ELISA-positive clones. Blots were incubated with hybridoma cell
supernatants and then with an HRP-labeled anti-mouse IgG
secondary antibody. The red (POM) numbers indicate the 19
selected mAbs used for further characterization. Numbers on top
indicate the individual clone numbers.
Found at: doi:10.1371/journal.pone.0003872.s001 (9.96 MB TIF)
Figure S2 First screen and selection of best performing clones.
Flow cytometric analysis of 55 clones using blood cells from mice
overexpressing PrPC on T-cells. Blood cells were incubated with
hybridoma cell supernatant or 6H4 and then incubated with a
fluorescently labeled anti-mouse IgG antibody. Staining for a T-
cell marker (CD3) allowed gating on T-cells and therefore analysis
of PrP-specific binding. Red boxes indicate the 19 selected mAbs
used in further characterization.
Found at: doi:10.1371/journal.pone.0003872.s002 (7.56 MB TIF)
Figure S3 Sandwich ELISA with biotinylated POMs confirms
SPR-results. (A)–(E) Each panel represents a 96-well plate
incubated with one biotinylated POM as indicated. All plates
were coated with unlabeled POM1, 2, 3, 4 and 9 as well as IgG1
for control. The results confirm that POM4 does not compete with
POM1 or POM9 and that the N-terminal POM2 and POM3 do
not compete with any of the C-terminal POM1 or POM9. At least
two molecules of POM2 can bind simultaneously to one molecule
of PrP.
Found at: doi:10.1371/journal.pone.0003872.s003 (8.46 MB TIF)
Figure S4 Screening of POMs for binding to N-terminally
truncated PrPs. (A) Equal amounts of brain proteins from wild
type, DE-PrP (with a deletion of amino acids 33–121) with a wild
type PrP allele, or two Prnpo/o mice were used on 12 replica blots,
incubated with the indicated POMs. All N-terminal specific
antibodies failed to recognize DE-PrP, confirming previous results.
POM5 and POM7 showed a mono- and unglycosylated-specific
binding pattern. (B) Replica blots with equal amounts of brain
proteins from wild type, DE-PrP with a wild type PrP allele, DF-
PrP (with a deletion of amino acids 33–134) or Prnpo/o mice
incubated with the indicated POMs. POM4 and 10 (and POM19,
not shown) did not recognize DF-PrP, suggesting that residues
121–134 are essential for the binding of these three antibodies.
KO: Brain homogenate from Prnpo/o mice.
Found at: doi:10.1371/journal.pone.0003872.s004 (8.16 MB TIF)
Figure S5 Binding of purified POM1–19 antibodies to cell-
surface PrPC. Flow cytometric analysis comparing all POM
antibodies to 6H4 for binding on PrPC-overexpressing T-cells.
Interestingly, all N-terminal specific POMs show very strong
binding to native PrPC as displayed on the surface of live cells.
Found at: doi:10.1371/journal.pone.0003872.s005 (7.31 MB TIF)
Figure S6 Protein sequence alignment of scFvs from selected
POMs and SDS-PAGE analysis of POM2 scFv purification. (A)
The three CDRs of the VL and VH are highlighted in pink for
CDR1, blue for CDR2 and green for CDR3. The amino acid
linker between the VL and VH domains spans amino acids 108 to
128. The C-terminal Histidine tag was incorporated into each of
the POM scFv sequences to enable purification by an affinity
column. (B) Although there appears to be some POM2 scFv
eluting from the column in the Flowthrough and the Wash
fraction, pure POM2 scFv (,27 kDa) is present primarily in the
Elution fractions. The gel was stained with Coomassie Brilliant
Blue R250.
Found at: doi:10.1371/journal.pone.0003872.s006 (9.71 MB TIF)
Figure S7 Plasmon Resonance experiments and affinity deter-
mination of selected POMs. (A) SPR analysis of POM19 binding
to immobilized rmPrP121 231. Purified POM19 was injected at
different concentrations - ranging from 110nM to 420pM - and
the binding constant was calculated with the BIAevaluation 3.1
software to be 870pM. (B) Affinity determination of scFv POM2
was done with competition SPR. First a standard curve of POM2
scFv with a panel of solutions at different antibody concentrations -
ranging from 12nM–125pM - was created (left panel). Then, a
series of pre-equilibrated solutions containing 6nM POM2 scFv
and various concentrations of the epitope-mimicking peptide - 13
different concentrations, ranging from 100-0.01nM - were tested
on the same chip in duplicates. We plotted the values of free
antibody against those of the peptide competitor using the
BIAevaluation software (right plot). The estimated equilibrium
dissociation constant of the single binding event of scFv POM2 to
the singular peptide epitope is 20nM.
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Found at: doi:10.1371/journal.pone.0003872.s007 (8.78 MB TIF)
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